Verrica stock drops after half patients’ tumours gone in skin cancer trial

Shares in Verrica Pharmaceuticals have dropped after the company revealed that half of the patients in its Phase II trial for basal cell carcinoma achieved complete response.

The company announced topline results from the second part of the Phase II trial on August 14 and as a result of the announcement, the stock price fell by 40%